CC-4047: Substrate potential in None assigned. To determine if a clinical drug-drug Q4 2013 Report) OATP1B1 and OATP1B3 expressing interaction study evaluating HEK293 cells. pomalidomide as a substrate of CC-4047-DMPK-1653 OATP1B1 or OATP1B3 may be Protocol synopsis available necessary. Population pharmacokinetics and Use in patients with Pharmacokinetic data from completed End of 2013 (Final Report) exposure response analysis plan of renal impairment studies in healthy subjects and MM pomalidomide. patients will be included in a population Use in patients with Protocol available pharmacokinetic analysis hepatic impairment The covariates to be included in the Use in patients of analysis will include, but not be limited different racial origin to, disease state, dose, formulation, fed state, age, weight, race, gender, creatinine clearance (mL/min) and markers of hepatic function, as available. Q=quarter
CC-4047: Substrate potential in OATP1B1 and OATP1B3 expressing HEK293 cells. CC-4047-DMPK-1653 Protocol synopsis available None assigned. To determine if a clinical drug-drug interaction study evaluating pomalidomide as a substrate of OATP1B1 or OATP1B3 may be necessary. Q4 2013 Report) Population pharmacokinetics and exposure response analysis plan of pomalidomide. Protocol available Use in patients with renal impairment Use in patients with hepatic impairment Use in patients of different racial origin Pharmacokinetic data from completed studies in healthy subjects and MM patients will be included in a population pharmacokinetic analysis The covariates to be included in the analysis will include, but not be limited to, disease state, dose, formulation, fed state, age, weight, race, gender, creatinine clearance (mL/min) and markers of hepatic function, as available. End of 2013 (Final Report) Q=quarter
auspar-pomalidomide-131014.docx